[Pantethine, diabetes mellitus and atherosclerosis. Clinical study of 1045 patients].
After a review of the clinical studies on the treatment of diabetic patients with pantethine, the authors discuss the results obtained in a postmarketing surveillance (PMS) study on 1045 hyperlipidemic patients receiving pantethine (900 mg/day on average). Of these patients, 57 were insulin-dependent (Type I) and 241 were non insulin-dependent (Type II) diabetics. Beyond the epidemiological considerations made possible by a PMS study, the authors show that pantethine brought about a statistically significant and comparable improvement of lipid metabolism in the three groups of patients, with very good tolerability. Pantethine should therefore be considered for the treatment of lipid abnormalities also in patients at risk such as those with diabetes mellitus.
Donati
C
C
Bertieri
R S
RS
Barbi
G
G
D001161:Arteriosclerosis / Q000209:etiology / Q000517:prevention & control; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy*; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy; D005260:Female; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010204:Pantetheine / Q000031:analogs & derivatives / Q000627:therapeutic use*; D011358:Product Surveillance, Postmarketing; D013438:Sulfhydryl Compounds / Q000627:therapeutic use*
D013438:Sulfhydryl Compounds; D010204:Pantetheine; C005425:pantethine
Pantetina, diabete e aterosclerosi. Indagine clinica su 1045 pazienti.